Financials

  • Market Capitalization 459.6 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.55
Price to sales ratio
2.05

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2970
PRTA
Prothena Corporation plc - Ordinary Shares
9.09 USD-1.73%-0.22%+5.21%+9.92%466.65 M USD
2973
OCGN
Ocugen, Inc. - Common Stock
1.37 USD-2.84%-2.14%+9.60%+31.73%464.58 M USD
2990
CMPX
Compass Therapeutics, Inc. - Common Stock
2.52 USD+3.70%+5.44%+24.14%-27.59%453.82 M USD
3020
AVIR
Atea Pharmaceuticals, Inc. - common stock
5.45 USD-1.09%+1.68%+23.30%+69.78%437.12 M USD

Frequently asked questions about Arcturus Therapeutics Holdings Inc. Common Stock

What is the Arcturus Therapeutics Holdings Inc. Common Stock stock price today?

The current price of Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) is 16.17. Over the past 24 hours, the stock has changed by +2.15%. Follow the ARCT chart for real-time price dynamics.

What is the stock ticker of Arcturus Therapeutics Holdings Inc. Common Stock?

Arcturus Therapeutics Holdings Inc. Common Stock trades under the ticker ARCT. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Arcturus Therapeutics Holdings Inc. Common Stock stock going up?

ARCT has changed by +45.28% over the last week, +181.22% over the last month, and -5.05% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Arcturus Therapeutics Holdings Inc. Common Stock?

Arcturus Therapeutics Holdings Inc. Common Stock currently has a market capitalization of 459.6 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Arcturus Therapeutics Holdings Inc. Common Stock earnings last quarter?

Last quarter, Arcturus Therapeutics Holdings Inc. Common Stock reported earnings of -0.84 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Arcturus Therapeutics Holdings Inc. Common Stock revenue for the last quarter?

Arcturus Therapeutics Holdings Inc. Common Stock reported quarterly revenue of 2.96 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Arcturus Therapeutics Holdings Inc. Common Stock net income for the last quarter?

Arcturus Therapeutics Holdings Inc. Common Stock reported net income of -23.79 M for the last quarter. The previous quarter showed -26.96 M, which means net income changed by +11.79%.

How many employees does Arcturus Therapeutics Holdings Inc. Common Stock have?

As of the latest available data, Arcturus Therapeutics Holdings Inc. Common Stock has 111 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Arcturus Therapeutics Holdings Inc. Common Stock stock?

You can buy Arcturus Therapeutics Holdings Inc. Common Stock (ARCT) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Arcturus Therapeutics Holdings Inc. Common Stock stock?

Investing in Arcturus Therapeutics Holdings Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ARCT chart and related analysis on metatrader.com as part of your research.

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

News